Background. Immunogenicity and safety of inactivated zoster vaccine (ZV IN ) were evaluated in adults with autoimmune disease. Methods. Adults with autoimmune disease treated with immunosuppressive therapy (biologic or nonbiologic) were randomized to receive 4 doses of ZV IN , ZV IN containing a higher quantity of antigen, or placebo. To measure varicella-zoster virus (VZV)-specific immune responses using glycoprotein enzyme-linked immunosorbent assay (gpELISA) and interferon-gamma enzyme-linked immunospot (IFN-γ ELISPOT), blood samples were collected at baseline, post-doses 2, 3, and 4. The primary hypothesis was that ZV IN would elicit significant VZV-specific immune responses, measured by gpELISA or ELISPOT, at approximately 28 days postdose 4. Safety and tolerability was assessed through 28 days post-dose 4.
immunosuppressive therapy [8, 12, 13] . In patients with inflammatory bowel disease (IBD), overall HZ incidence ranges from approximately 3 to 13/1000 PY and increases in patients who are receiving a combination therapy, including anti-tumor necrosis factor alpha (TNF-α) with thiopurine and/or steroids [8, 10, 14] . Current data on incidence rates of HZ in patients with other autoimmune diseases (eg, ankylosing spondylitis [AS], multiple sclerosis [MS] , and psoriasis [PsO] ) are scarce. Recently, incidence rates of HZ of approximately 9/1000 PY were reported for AS, MS, and PsO [8, 10, 15] .
ZV is licensed to prevent or attenuate HZ and its complications, including prevention of post-herpetic neuralgia (PHN) and reduction of acute and chronic pain associated with HZ in immunocompetent adults aged ≥50 years. However, ZV is contraindicated in immunocompromised patients [16] .
Therefore, an investigational inactivated ZV (ZV IN ) is being developed for the prevention and amelioration of HZ and HZ-related complications in the immunocompromised population. Proof-of-concept and phase 1 studies demonstrated safety, efficacy, and immunogenicity of ZV IN when administered as a 4-dose regimen in immunocompromised patients [17] [18] [19] .
Our objectives in this phase 2 study were to demonstrate the immunogenicity and safety of ZV IN in patients with RA, SLE, IBD, AS, MS, PsO, and other autoimmune diseases receiving immunosuppressive therapy who are receiving either biologic or non-biologic immunosuppressive therapy.
METHODS

Study Design
This phase 2, randomized, double-blind, placebo-controlled, multicenter study (62 study sites across 12 countries) evaluated the immunogenicity and safety of ZV IN in adults with autoimmune disease receiving immunosuppressive therapy. Approximately 340 patients were planned to be randomized, via an interactive voice response system, to receive a 4-dose regimen administered 21 to 35 days apart of ZV IN (approximately 180 recipients), ZV IN 
Study Population
This study was conducted in accordance with the Principles of Good Clinical Practice, approved by the ethical review committee of each participating site. Written informed consent was obtained from each patient prior to study entry.
The study population included patients aged ≥18 years diagnosed with an autoimmune disease who had been clinically stable for ≥30 days prior to enrollment and not likely to undergo hematopoietic stem cell transplant during the study. Patients with a history of varicella or residence in a VZV-endemic area for ≥30 years and patients who were aged <30 years and attended primary or secondary school in a country with endemic VZV infection were eligible for the study. Patients were to be on ≥1 biologic agent, such as a TNF-α inhibitor or a nonbiologic immunosuppressive therapy, at a stable dose for ≥3 months, with no planned or anticipated changes in treatment regimen at the time of enrollment. Minimum doses were required for the following monotherapy treatments: methotrexate, >0.4 mg/kg/week; sulfasalazine or mycophenolate mofetil, ≥2 g/day; azathioprine, >3.0 mg/kg/day; 6-mercaptopurine, >1.5 mg/kg/day; and prednisone or equivalent, >20 mg/day (further details are provided in the Supplementary Materials).
Vaccine Description
The lyophilized ZV IN (lots WL00039143, WL00039144, WL00039145, and WL00039146 [ZV IN High Ag]) and placebo (lot WL00040483; ZV IN stabilizer without virus antigen) were stored at 2°C-8°C or colder until reconstitution. The diluent (lot WL00045837), 0.7 mL of sterile water without preservatives, was stored at room temperature or at 2°C-8°C. The vaccines and placebo were reconstituted by withdrawing the entire contents of the diluent vial into a syringe, injecting the entire contents of the syringe into the vial of study vaccine, and gently agitating the mixture. All patients received a single 0.5-mL subcutaneous injection of ZV IN , ZV IN High Ag, or placebo administered as a 4-dose regimen.
Study Objectives
In adult patients with autoimmune disease, the primary objectives were to determine whether ZV IN 
Immunogenicity Measurements
Serum samples to measure VZV antibody concentrations by gpELISA and whole blood samples to detect IFN-γ-secreting VZV-specific cell responses from peripheral blood mononuclear cells via ELISPOT were collected from all patients on day 1 (prior to dose 1) and at visit 5 (approximately day 118, 28-35 days post-dose 4) (further details are provided in the Supplementary Materials). Additionally, half of the study population (approximately 170 patients) was assigned to have blood collected at visit 3 (approximately day 60, 21-35 days postdose 2), and the other half (approximately 170 patients) was assigned to have blood collected at visit 4 (approximately day 90, 21-35 days post-dose 3).
Safety Surveillance
The safety and tolerability profile following all 4 vaccine doses was based on the incidence of serious adverse experiences (SAEs) observed during the period up to 28 days post-dose 4 in each vaccination group (ie, all ZV IN group [including ZV IN High Ag] and the placebo group). Daily oral temperature readings and injection-site and systemic AEs that occurred through 28 days post-dose 4 were recorded on a vaccination report card (VRC). However, injection-site redness, swelling, and pain/tenderness were solicited on the VRC for 5 days after each vaccination dose and continued to be collected through 28 days post-dose 4.
Patients who developed suspected varicella/varicella-like or HZ/HZ-like rashes during the follow-up period through 28 days post-dose 4 were instructed to contact the investigator as soon as possible after rash onset (preferably within 24 to 72 hours) for clinical evaluation and to collect lesion swabs for polymerase chain reaction (PCR) analysis.
Statistical Methods
Immunogenicity
The primary hypothesis was that ZV IN The primary immunogenicity analysis was based on the per-protocol population, according to the actual vaccination received, using a longitudinal regression model in ZV IN recipients only (excluding ZV IN High Ag) [20] . Log-transformed VZV responses at each visit were used as response variables, with visit and stratification factor as covariates (further details are provided in the Supplementary Materials). Since there were 2 hypothesis tested (gpELISA and ELISPOT), a step-up procedure was used to adjust for multiplicity [21] .
Safety
All patients who received ≥1 dose of vaccine and had any safety follow-up were included in the safety evaluation, based on the actual vaccination received (ie, all patients as treated). Safety analyses were based on all ZV IN data (including ZV IN High Ag).
Key safety measures included proportions of patients with any AE, injection-site AE, systemic AE, SAE, vaccine-related SAE, and discontinuation due to an AE after any study vaccination through 28 days post-dose 4 in each vaccination group. For these measurements, 95% confidence intervals (CIs) of the risk difference between all ZV IN vaccine (including ZV IN High Ag) and placebo groups were examined [22] .
RESULTS
Participant Accounting and Demographics
Overall, 354 patients were randomized: 190 to the ZV IN group, 102 to the ZV IN High Ag group, and 62 to the placebo group ( Figure 1) ; 94.6% (335/354) of enrolled patients completed the 4-dose regimen and all study visits. Nineteen patients discontinued from the study (Figure 1 ). Table 1 displays the similar demographic composition of the participants in the treatment groups. Participants were predominantly white, non-Hispanic/Latino, and female. The mean age across all treatment groups was similar. Approximately onehalf of the patients were enrolled into each of the study strata: biologic and nonbiologic therapy (Supplementary Tables 1 and  2 ). Overall, the most common primary autoimmune diseases reported among ZV IN and placebo recipients included RA, PsO, and SLE (Table 2 ). Among patients in the biologic and nonbiologic therapy strata, the most common diagnoses included PsO, RA, and Crohn's disease and RA, SLE, and MS, respectively.
The most frequently reported specific medical history terms were balanced across all 3 vaccination groups (Supplementary Table 3 ). For patients with autoimmune diseases, the most frequently used prior and concomitant medications were expected (Supplementary Table 4 ).
Immunogenicity
For the primary immunogenicity analyses, the ZV IN (excluding ZV IN High Ag) elicited statistically significant VZV-specific immune responses measured by either gpELISA or VZV IFN-γ ELISPOT at approximately 28 days post-dose 4 ( Table 3 ). The estimated GMFR of the VZV-specific antibody response measured by gpELISA at approximately 28 days post-dose 4 was 1.6 (95% CI, 1.4-1.7; P < .0001). The estimated GMFR of the VZVspecific cell-mediated immune response measured by IFN-γ ELISPOT at approximately 28 days post-dose 4 was 2.0 (95% CI, 1.6-2.6; P < .0001).
Observed immune responses were consistent with the results of the primary immunogenicity analysis at approximately 28 days post-dose 4 (gpELISA GMFR 1.6; 95% CI, 1.5-1.7), ELISPOT GMFR 2.0 (95% CI, 1.7-2.5); (Table 4 ). In addition, at approximately 28 days post-dose 4, observed gpELISA GMFRs were 2.2 and 1.0, and the IFN-γ ELISPOT GMFRs were 1.6 and 0.9 for ZV IN High Ag and placebo, respectively (Supplementary  Tables 5 and 6 ).
For patients receiving biologic therapy, the post-dose 4 gpELISA GMFRs were 1.5, 1.8, and 1.0 for ZV IN , ZV IN High Ag, and placebo, respectively. The corresponding post-dose 4 IFN-γ ELISPOT GMFRs were 2.0, 1.7, and 0.9 (Table 4, Supplementary  Tables 5 and 6 ). For patients receiving nonbiologic therapy, the post-dose 4 gpELISA GMFRs were 1.6, 2.8, and 0.9 for ZV IN , ZV IN High Ag, and placebo, respectively. The corresponding post-dose 4 IFN-γ ELISPOT GMFRs were 2.0, 1.6, and 0.9 (Table 4, Supplemental Tables 5 and 6 ). Not Randomized n =8 Figure 1 . Patient participation. *One patient, enrolled in the biologic therapy stratum and randomized to the inactivated zoster vaccine group, was discontinued due to a post-randomization exclusion discovery (screen failure).
Safety
All randomized participants who received ≥1 dose of study vaccination and had safety follow-up were included in the safety analyses (Table 5) Primary immunogenicity analysis is calculated based on a single longitudinal regression model adjusting for prevaccination values and excludes recipients of inactivated zoster vaccine containing a higher quantity of antigen and placebo recipients.
Abbreviations: CI, confidence interval; GMC, geometric mean count; GMFR, geometric mean fold rise from baseline; GMT, geometric mean titer; gpELISA, glycoprotein enzyme-linked immunosorbent assay; IFN-γ ELISPOT, interferon-gamma enzyme-linked immunospot assay; VZV, varicella-zoster virus. a Number of patients with valid results at baseline or the time points post baseline. respectively); all were considered vaccine related per-protocol. The most frequently reported injection-site AEs were erythema, pain, and swelling; the majority were reported as grade 1 (does not interfere with activity) according to the protocol-specified grading scale. Additionally, the majority of injection-site AEs was reported as mild in intensity; only 1 patient reported experiencing severe injection-site pain. Table 8) .
Eleven SAEs were reported among 9 study participants, with 2 events (keratitis [with a secondary bacterial infection] and amnesia; both in ZV IN group) determined by the investigator to be vaccine related (Table 6 ). One patient with SLE, enrolled in the nonbiologic stratum, died while recovering from an SAE (respiratory distress) that developed on day 24 post-dose 4. This SAE was assessed as not vaccine related by the investigator; the cause of death was pulseless electrical activity arrest.
During the study, 10 patients (6 in ZV IN group, 1 in ZV IN High Ag group, 3 in placebo group) reported 12 varicella or varicella-like HZ or HZ-like rashes. PCR analysis was conducted for 6 rashes for which lesion specimens were submitted and adequate for testing; none were positive for vaccine-strain VZV (Oka/ Merck). One specimen, which tested positive for wild-type VZV, was collected from a placebo recipient with Wegener's granulomatosis treated with azathioprine and prednisolone. The rash started 11 days post-dose 2 with a maximum of 1-25 lesions. The patient was diagnosed with HZ and treated with acyclovir. The rash, which was mild in intensity, resolved within 42 days.
DISCUSSION VZV-specific cell-mediated immunity is crucial for preventing reactivation of VZV and subsequent onset of HZ [8, 23] . Immunocompromised patients exhibit increasing susceptibility to VZV reactivation as seen in RA, PsO, SLE, and IBD [8, 10, 11, 15] . In addition, these patients often receive immunosuppressive Immunogenicity analyses presented exclude recipients of inactivated zoster vaccine containing a higher quantity of antigen and placebo recipients.
Abbreviations: CI, confidence interval; GMC, geometric mean count; GMFR, geometric mean fold rise from baseline; GMT, geometric mean titer; gpELISA, glycoprotein enzyme-linked immunosorbent assay; IFN-γ ELISPOT, interferon-gamma enzyme-linked immunospot assay; VZV, varicella-zoster virus. a Number of patients contributing to analysis.
therapy, which further increases the risk of developing HZ by approximately 50% [4] . Severe immunosuppression may also result in severe HZ-related complications such as myelitis, pneumonitis, encephalitis, and disseminated visceral disease [24] . Higher frequencies of HZ-related hospitalization and persistent PHN have been commonly observed with the use of biologics, such as anti-TNF-α monoclonal antibodies [13, 25] . Currently, ZV IN is being developed for the prevention and amelioration of HZ and HZ-related complications in immunocompromised patients [17] [18] [19] . In this phase 2 study, ZV IN , ZV IN High Ag, or placebo were administered to patients with autoimmune disease who were receiving either a biologic or a nonbiologic therapy.
The 4-dose ZV IN vaccine was immunogenic in adults with autoimmune disease. VZV-specific immune responses did not consistently increase with dose 3 and dose 4. The primary study objective was met whereby ZV IN elicited statistically significant VZV-specific antibody and cell-mediated immune responses, measured by gpELISA and VZV IFN-γ ELISPOT, at approximately 28 days post-dose 4. VZV-specific antibody response, in addition to VZV cell-mediated immunity, correlated with protection against HZ as demonstrated in ZV phase 3 clinical trials, but neither trial established a titer of VZV antibody that would serve as a surrogate of protection [26] . Therefore, VZVspecific immune responses observed after 4 doses of ZV IN vaccine in this trial might suggest the potential for reduction of HZ Number of subjects in each category. c Determined by the investigator to be possibly, probably, or definitely related to the vaccine. VZV-specific immune responses were generally comparable between patients receiving biologic and nonbiologic therapy. These findings are encouraging because patients with autoimmune disorders who receive either biologic therapies or nonbiologic treatment are at increased risk for HZ.
The 4-dose ZV IN vaccine was well tolerated in adults with autoimmune disease. The majority of injection-site AEs was reported as mild in intensity. The most frequently reported injection-site AEs, erythema, pain, and swelling, were reported as grade 1 (does not interfere with activity). As expected, a significantly higher proportion of injection-site AEs was observed in all ZV IN (including ZV IN High Ag) recipients when compared to placebo recipients. Similar results were observed irrespective of biologic and nonbiologic therapy. The overall proportions of SAE between the ZV IN and placebo groups were similar. While 1 patient with a history of global transitory amnesia and migraines developed amnesia, determined by the investigator to be vaccine related, to our knowledge there are no reports of amnesia associated with ZVs.
One limitation of this study is the enrollment of a heterogeneous patient population with regard to autoimmune disease diagnosis and immunosuppressive treatment. Furthermore, it is currently unknown whether VZV-specific immune responses in this study following ZV IN administration correlate with vaccine efficacy in immunocompromised patients, including patients with autoimmune diseases, and whether these levels of VZVspecific immune response would provide meaningful reduction in HZ and HZ-related complications. Given that the increase in VZV-specific antibody and T-cell responses, measured by gpELISA and IFN-γ ELISPOT, correlated with vaccine efficacy for ZV against HZ in immunocompetent older adults and that 4 doses of ZV IN in this trial elicited statistically significant VZVspecific immune responses in patients with autoimmune disease, ongoing safety and efficacy phase 3 trials of ZV IN in other immunocompromised populations will be of interest [23, 27] .
In conclusion, ZV IN was well tolerated and elicited statistically significant VZV-specific immune responses approximately 28 days post-dose 4, measured by gpELISA and IFN-γ ELISPOT, when administered to adults with autoimmune disease and on immunosuppressive therapy. The results of this phase 2 study might provide relevant information for this patient population One patient (aged 54 years) from ZV IN high-antigen nonbiologic stratum reported a serious AE of pneumonia outside 28 days follow-up on day 43 post-dose 3 for a duration of 11 days; the patient did not discontinue the study.
Abbreviation: AE, adverse event; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; ZV IN , inactivated zoster vaccine. a Day of relative onset is with regard to the most recent vaccination dose and not to study start.
b Serious AE not resolved by the end of the study.
c Determined by the investigator to be possibly, probably, or definitely related to the vaccine.
d One patient with SLE, enrolled in the nonbiologic stratum, died while recovering from serious AE (respiratory distress) that developed on day 24 post-dose 4. This serious AE was assessed as not vaccine related by the investigator; the cause of death was pulseless electrical activity arrest.
who may benefit from prevention of HZ and HZ-related complications should the results of the ongoing phase 3 studies confirm efficacy, immunogenicity, and safety of the ZV IN vaccine.
